RxDoctor Payments Data

Patricia Rahal

Critical Care Medicine · Vero Beach, FLNPI 1952682460

Payments from drug & device makers

$2,485in general payments, 2019–2025

Across 44 payments — averaging $56.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$550
  • Cvrx, Inc.$478
  • Abbott$426
  • AbbVie$245
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$174
  • Pfizer$128
  • plus $484 from 5 others

What the payments were for

  • Food & beverage$2,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,485 in reported general payments places this provider in the 80th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$23,802
Medicare patients
255
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban375$481,556
EntrestoSacubitril/Valsartan103$127,246
JardianceEmpagliflozin93$115,477
XareltoRivaroxaban77$102,775
Repatha SureclickEvolocumab45$48,179
FarxigaDapagliflozin Propanediol29$34,068
InpefaSotagliflozin12$8,226
Metoprolol Succinate482$7,326
Atorvastatin Calcium415$4,382
Dabigatran EtexilateDabigatran Etexilate Mesylate14$4,380
Dofetilide16$4,049
Valsartan141$3,649
Rosuvastatin Calcium308$3,480
Carvedilol244$2,459
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$2,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$481,556375 claims
NovartisEntresto$29$127,246103 claims
Lexicon Pharmaceuticals, Inc.Inpefa$125$8,22612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →